Telix Pharmaceuticals reports $804 million in full-year revenue, with a 46% increase in Q4 revenue reaching $208 million.

Telix Pharmaceuticals Limited reported its fiscal 2025 revenue of approximately $804 million, meeting its upgraded guidance of $800-$820 million. The company saw a significant 46% year-over-year increase in fourth-quarter revenue, totaling around $208 million. The Precision Medicine business generated about $161 million in revenue, showing a 4% quarter-over-quarter growth. Telix is making progress with its clinical studies, treating international patients in the ProstACT Global Phase 3 study and SOLACE Phase 1 study in the U.S. They also dosed the first patient in the U.S. in the BiPASS Phase 3 trial. Telix stock is at lows, possibly due to testing lower boundaries.